Showing results (1-10 of 24) with videos related to
Sort By:
Pageof 3
Expert Review of Molecular Diagnostics|November 5, 2016
Towards diagnostic application of non-coding RNAs in neuroblastomaKristina Althoff, Johannes H Schulte, Alexander SchrammClinical & Experimental Ophthalmology|September 21, 2016
Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell linesMelanie Schwermer, Sabine Dreesmann, Angelika Eggert, et al.Angewandte Chemie (International Ed. in English)|October 5, 2019
Covalent-Allosteric Inhibitors to Achieve Akt Isoform-SelectivityLena Quambusch, Ina Landel, Laura Depta, et al.Journal for Immunotherapy of Cancer|May 21, 2021
Druggable epigenetic suppression of interferon-induced chemokine expression linked to MYCN amplification in neuroblastomaJohanna A Seier, Julia Reinhardt, Kritika Saraf, et al.Oncotarget|April 22, 2017
RITA displays anti-tumor activity in medulloblastomas independent of TP53 statusAline Gottlieb, Kristina Althoff, Laura Grunewald, et al.Oncotarget|November 16, 2013
BET bromodomain protein inhibition is a therapeutic option for medulloblastomaAnton Henssen, Theresa Thor, Andrea Odersky, et al.Oncotarget|October 9, 2014
MYCN-targeting miRNAs are predominantly downregulated during MYCN‑driven neuroblastoma tumor formationAnneleen Beckers, Gert Van Peer, Daniel R Carter, et al.International Journal of Cancer|February 13, 2013
MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1AKristina Althoff, Anneleen Beckers, Andrea Odersky, et al.Cancer Letters|January 7, 2019
Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastomaYoujia Han, Sven Lindner, Yi Bei, et al.Oncotarget|November 27, 2016
Targeting tachykinin receptors in neuroblastomaAnton G Henssen, Andrea Odersky, Annabell Szymansky, et al.Pageof 3